Vericel Corp Ord (VCEL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vericel Corp Ord (VCEL) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.01 Million) by net assets ($354.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VCEL market cap overview for the company's overall valuation and market capitalisation.
Vericel Corp Ord - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Vericel Corp Ord's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vericel Corp Ord Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vericel Corp Ord ranked by their cash flow conversion efficiency. Explore how high is Vericel Corp Ord's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Believe SAS
PA:BLV
|
0.049x |
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
0.000x |
|
Sharplink Gaming Ltd
NASDAQ:SBET
|
-0.005x |
|
Dunelm Group plc
F:DFQ
|
0.329x |
|
SLC Agrícola S.A
SA:SLCE3
|
0.152x |
|
Century Communities Inc
NYSE:CCS
|
-0.018x |
|
Century Plyboards (India) Limited
NSE:CENTURYPLY
|
0.116x |
|
Ashtrom Group Ltd
TA:ASHG
|
-0.090x |
Annual Cash Flow Conversion Efficiency for Vericel Corp Ord (1995–2025)
The table below shows the annual cash flow conversion efficiency of Vericel Corp Ord from 1995 to 2025. View Vericel Corp Ord stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $354.64 Million | $51.91 Million | 0.146x | -26.52% |
| 2024-12-31 | $291.97 Million | $58.16 Million | 0.199x | +27.47% |
| 2023-12-31 | $225.95 Million | $35.31 Million | 0.156x | +69.89% |
| 2022-12-31 | $192.27 Million | $17.69 Million | 0.092x | -46.00% |
| 2021-12-31 | $170.46 Million | $29.04 Million | 0.170x | +30.17% |
| 2020-12-31 | $134.26 Million | $17.57 Million | 0.131x | +302.42% |
| 2019-12-31 | $111.09 Million | $-7.18 Million | -0.065x | -1504.40% |
| 2018-12-31 | $102.23 Million | $-412.00K | -0.004x | +99.31% |
| 2017-12-31 | $22.54 Million | $-13.18 Million | -0.585x | +27.35% |
| 2016-12-31 | $24.71 Million | $-19.89 Million | -0.805x | -33.49% |
| 2015-12-31 | $22.13 Million | $-13.35 Million | -0.603x | +15.41% |
| 2014-12-31 | $35.64 Million | $-25.41 Million | -0.713x | +86.08% |
| 2013-12-31 | $3.89 Million | $-19.94 Million | -5.121x | -64.90% |
| 2012-12-31 | $9.51 Million | $-29.55 Million | -3.106x | -264.48% |
| 2011-12-31 | $-12.97 Million | $-24.49 Million | 1.888x | +136.58% |
| 2010-12-31 | $2.92 Million | $-15.09 Million | -5.163x | -546.36% |
| 2009-12-31 | $17.28 Million | $-13.80 Million | -0.799x | +4.56% |
| 2008-12-31 | $23.33 Million | $-19.53 Million | -0.837x | -59.46% |
| 2007-12-31 | $28.25 Million | $-14.83 Million | -0.525x | -64.38% |
| 2006-12-31 | $42.34 Million | $-13.52 Million | -0.319x | +4.70% |
| 2005-12-31 | $33.03 Million | $-11.06 Million | -0.335x | +38.07% |
| 2004-12-31 | $17.61 Million | $-9.53 Million | -0.541x | +30.35% |
| 2003-12-31 | $11.57 Million | $-8.99 Million | -0.777x | +4.10% |
| 2002-12-31 | $10.80 Million | $-8.75 Million | -0.810x | -38.68% |
| 2001-12-31 | $10.89 Million | $-6.36 Million | -0.584x | -5.60% |
| 2000-12-31 | $12.44 Million | $-6.88 Million | -0.553x | +57.97% |
| 1999-12-31 | $8.51 Million | $-11.20 Million | -1.316x | +8.75% |
| 1998-12-31 | $10.85 Million | $-15.64 Million | -1.442x | -103.97% |
| 1997-12-31 | $18.81 Million | $-13.30 Million | -0.707x | +11.77% |
| 1996-12-31 | $16.60 Million | $-13.30 Million | -0.801x | +57.74% |
| 1995-12-31 | $4.80 Million | $-9.10 Million | -1.896x | -- |
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more